COMPANY RESEARCHThe company's interim report describes peptidomimetic macrocycle discovery, optimization, and oral applications. DEL and platform capabilities do not establish human oral evidence for proprietary candidates.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 525,571,768.68 | 109,505,443.81 Net income attributable to shareholders of the listed company | 216,347,757.1 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 549,978,876.88 | 139,415,069.57 Net income attributable to shareholders of the listed company | 180,509,466.49 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
The company's interim report describes peptidomimetic macrocycle discovery, optimization, and oral applications. DEL and platform capabilities do not establish human oral evidence for proprietary candidates.
Provides research services using DEL, FBDD/SBDD, and other small-molecule discovery platforms and emerging technologies, alongside proprietary discovery and translation.
Listed as SSE 688222; original 2025 annual and 2026Q3 (YTD) reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Cyclic peptide-like / DEL platform for oral applications | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
| DEL / FBDD / SBDD drug discovery | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
HitGen reported consolidated revenue of RMB0.550 billion, up 48.73%, and attributable net income of RMB139.4 million for the nine months ended September 30, 2026. Attributable net income increased 50.11%. These are consolidated year-to-date figures rather than third-quarter-only results. The quarterly filing is unaudited and covers the year-to-date period.
HitGen researchers describe a method for synthesizing DNA-encoded bicyclic peptides using cysteine-promoted cyclization and amide condensation under mild conditions. The abstract reports compatibility with varied sequences and ring sizes. This is discovery-platform chemistry, not evidence that the resulting peptides have oral exposure, clinical efficacy, or validated manufacturing-scale performance.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.